Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$739M | — | — | -1418.8% | -163.7% | -$610M | — | $230M |
| 2024 | — | -$846M | — | — | -199.9% | -137.6% | -$587M | — | $99M |
| 2023 | — | -$408M | — | — | -95.4% | -79.5% | -$335M | — | $248M |
| 2022 | — | -$570M | — | — | -105.8% | -86.2% | -$304M | — | $205M |
| 2021 | — | -$214M | — | — | -616.3% | -150.5% | -$147M | — | $76M |
| 2020 | — | -$119M | — | — | -707.2% | — | -$77M | — | $83M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$137M | — | — | -1123.5% | -37.0% | -$86M | — | $238M |
| Mar '26 | — | -$131M | — | — | -100.8% | -28.0% | -$150M | — | $273M |
| Dec '25 | — | -$146M | — | — | -279.5% | -32.2% | -$131M | — | $230M |
| Sep '25 | — | -$173M | — | — | 1010.7% | -42.4% | -$146M | — | $185M |
| Jun '25 | — | -$198M | — | — | -147.2% | -36.0% | -$168M | — | $166M |
| Mar '25 | — | -$222M | — | — | -85.4% | -48.3% | -$166M | — | $98M |
| Dec '24 | — | -$187M | — | — | -44.1% | -30.4% | -$171M | — | $99M |
| Sep '24 | — | -$160M | — | — | -50.7% | -31.4% | -$142M | — | $84M |
| Jun '24 | — | -$320M | — | — | -83.3% | -54.9% | -$171M | — | $239M |
| Mar '24 | — | -$180M | — | — | -59.5% | -42.9% | -$103M | — | $183M |
| Dec '23 | — | -$145M | — | — | -33.8% | -28.2% | -$115M | — | $248M |
| Sep '23 | — | -$103M | — | — | -35.4% | -26.8% | -$96M | — | $112M |
| Jun '23 | — | -$90M | — | — | -23.3% | -17.8% | -$45M | — | $148M |
| Mar '23 | — | -$70M | — | — | -14.9% | -11.4% | -$78M | — | $125M |
| Dec '22 | — | -$201M | — | — | -37.3% | -30.4% | -$76M | — | $205M |
| Sep '22 | — | -$69M | — | — | -68.7% | -50.8% | -$100M | — | $51M |
| Jun '22 | — | -$203M | — | — | -813.2% | — | -$69M | — | $23M |
| Mar '22 | — | -$97M | — | — | -210.5% | — | -$59M | — | $40M |
| Dec '21 | — | -$52M | — | — | -149.6% | -36.5% | -$33M | — | $76M |
| Sep '21 | — | -$54M | — | — | -16.9% | — | — | — | $362M |
See the revenue and net-income charts above for Biohaven Ltd.'s multi-year trend.
As of FY2025, Biohaven Ltd. reported — of total debt against $230M of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.